Pellini Michael J
Known title: DirectorCIK: 0001402017
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
Transaction History
| ADPT | ▲ Buy | Grant | 15,394 | $0 | 3/4/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 31,328 | $0 | 3/4/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 14,775 | $0 | 3/6/2023 | View on chart |
| WGS | ▲ Buy | Option Exercise | 4,278 | — | 10/15/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,836 | — | 4/27/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 6,689 | $0 | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.